Haematological consequences of parvovirus B19 infection

Bailliere's Best Practice and Research in Clinical Haematology

Volumn 13, Issue 2, 2000, Pages 245-259

  Brown, Kevin E ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Bone marrow disease; Erythrovirus; Haematopoiesis; Parvovirus B19 infection; Red cell aplasia

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD GROUP ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEUTRALIZING ANTIBODY; PARVOVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS CAPSID ANTIGEN; VIRUS DNA; VIRUS VACCINE;

ADULT; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW BIOPSY; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CYTOTOXICITY; ERYTHEMA INFECTIOSUM; ERYTHROBLAST; ERYTHROPOIESIS; FEMALE; FETUS HYDROPS; FETUS MORTALITY; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HOST SUSCEPTIBILITY; HUMAN; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PARVOVIRUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PURE RED CELL ANEMIA; STEM CELL; TAXONOMY; VACCINE PRODUCTION; VIROGENESIS; VIRUS CHARACTERIZATION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 0033693011     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0071     Document Type: Article

References (79)

1. Parvovirus-like particles in human sera
2. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia
3. Outbreak of aplastic crisis in sickle cell anaemia associated with parvovirus-like agent
4. Human parvovirus, the cause of erythema infectiosum (fifth disease)?
5. An outbreak of erythema infectiosum associated with human parvovirus infection
6. Detection of antibodies to human parvovirus in erythema infectiosum (fifth disease)
7. An erythema infectiosum-like illness caused by human parvovirus infection
8. Characteristics and taxonomy of Parvoviridae
9. Family Parvoviridae
10. Identification of a novel simian parvovirus in cynomolgus monkeys with severe anemia: A paradigm of human B19 parvovirus infection
11. Experimental infection of cynomolgus monkeys with simian parvovirus
12. The simian parvoviruses
13. Cloning of the human parvovirus B19 genome and structural analysis of its palindromic termini
14. In vitro identification of a B19 parvovirus promoter
15. Novel transcription map for the B19 (human) pathogenic parvovirus
16. Replication of the B19 parvovirus in human bone marrow cell cultures
17. Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures
18. Human parvovirus B19 nonstructural (NSI) protein induces apoptosis in erythroid lineage cells
19. Possible interactions between the NS-I protein and tumour necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19
20. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions
21. The structure of human parvovirus B19 at 8 Å resolution
22. Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor
23. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface
24. Genetic diversity of human parvovirus B19 determined using a set of restriction endonucleases recognizing four or five base pairs and partial nucleotide sequencing: Use of sequence variability in virus classification
25. Genetic diversity of human parvovirus B19: Sequence analysis of the VP1/VP2 gene from multiple isolates
26. Novel human erythrovirus associated with transient aplastic anemia
27. Erythrocyte P antigen: Cellular receptor for B19 parvovirus
28. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen)
29. Tissue distribution of H. Lewis and P antigens as shown by a panel of 18 monoclonal antibodies
30. A human parvovirus-like virus inhibits haematopoietic colony formation in vitro
31. Ultrastructural features of fetal erythroid precursors infected with parvovirus B19 in vitro: Evidence of cell death by apoptosis
32. A cytotoxic nonstructural protein, NSI, of human parvovirus B19 induces activation of interleukin-6 gene expression
33. Human parvovirus B19 infections in women of childbearing age and within families
34. Experimental parvoviral infection in humans
35. Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19)
36. Parvovirus and idiopathic thrombocytopenic purpura
37. Lack of evidence for parvovirus B19 viraemia in children with chronic neutropenia
38. Parvovirus B19-associated haemophagocytic syndrome in healthy adults
39. Viral-associated haemophagocytosis with parvovirus-B19-related pancytopenia
40. Parvovirus B19-associated hemophagocytic syndrome
41. Characterization of a virus that causes transient aplastic crisis
42. Polymerase chain reaction amplification of archival material for parvovirus B19 in children with transient erythroblastopenia of childhood
43. Clinical manifestations of human parvovirus B19 in adults
44. Human parvovirus arthropathy and rheumatoid factor
45. Human parvovirus B19 in rheumatoid arthritis
46. Human parvovirus B19 as a causative agent for rheumatoid arthritis
47. A study of the role of parvovirus B19 in rheumatoid arthritis
48. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy
49. Unusual manifestations of infection
50. Hepatitis-associated aplastic anemia and acute parvovirus B19 infection: A report of two cases and a review of the literature
51. Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children
52. Human parvovirus B19 infection and hepatitis
53. Parvovirus B19 infection and fulminant hepatitis
54. Human parvovirus B19 infection associated with acute hepatitis
55. Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia
56. Congenital hemolytic jaundice: The pathogenesis of the 'hemolytic crisis'
57. Hematologic and hematopoietic consequences of B19 parvovirus infection
58. Chronic bone marrow failure due to persistent B19 parvovirus infection
59. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type-I (HIV-I): A treatable cause of anemia in AIDS
60. Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia
61. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy
62. Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection
63. Immune response to B19 parvovirus and an antibody defect in persistent viral infection
64. Human parvovirus B19 (HPV B19) is not a rare cause of anemia in HIV-seropositive individuals
65. Prospective study of human parvovirus (B19) infection in pregnancy
66. Immediate and long term outcome of human parvovirus B19 infection in pregnancy
67. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis
68. The frequency of human parvovirus B19 infection in nonimmune hydrops fetails
69. Congenital anaemia after transplacental B19 parvovirus infection
70. Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection
71. Characterization of a nested polymerase chain reaction assay for detection of parvovirus B19
72. Evidence for persistence of human parvovirus B19 DNA in bone marrow
73. Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV)
74. Transmission of human parvovirus B19 by coagulation factor concentrates
75. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: Implications for efficiency and consistency of removal of B19 DNA during manufacture
76. Clinical and epidemiological features of simian parvovirus infection in cynomolgus macaques with severe anemia
77. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions
78. Candidate recombinant vaccine for human B19 parvovirus